TEMPUS AI INC CLASS A (TEM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for TEM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TEM | Director | 64 | ["Chairman and CEO of Ottimo Pharma Limited since October 2024","Board member at Valo Health, LLC and Agomab Therapeutics NV","Director at Three Opinions Foundation Inc and Pelican Harbor Seabird Station","Former CEO and board member of Seagen Inc.","Leadership roles at multiple biotherapeutics companies","B.S. in pharmacy from Rutgers University College of Pharmacy","M.B.A. in finance and marketing from Columbia University Graduate School of Business","Extensive experience in executive roles in the life sciences industry"] | ["Compensation Committee","Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IFF | Executive Partner, Flagship Pioneering; Director | 58 | ["Executive Partner at Flagship Pioneering","Former Division Head and CEO of Novartis Pharmaceuticals","Former President and CEO of Novartis Oncology division","Experience with Sandoz and Novartis in leadership positions","Former associate at Booz Allen Hamilton"] | ["Nom.& Gov.","Nominating and Governance"] | 2020 |
Biography sourced from the proxy statement filing.
David R. Epstein has served as a member of our board of directors since February 2024. Mr. Epstein has served as the Chairman and Chief Executive Officer of Ottimo Pharma Limited since October 2024. Mr. Epstein also serves as a board member at privately held biotherapeutics companies Valo Health, LLC, and Agomab Therapeutics NV. He is a Director at the non-profit Three Opinions Foundation Inc and at South Florida s Pelican Harbor Seabird Station. Mr. Epstein previously served as the Chief Executive Officer and a member of the board of directors of Seagen Inc. from November 2022 until Seagen s acquisition by Pfizer Inc. in December 2023. From October 2021 to December 2023, Mr. Epstein served on the board of directors of OPY Acquisition Corp. I. From June 2022 to June 2023, Mr. Epstein served as a member of the board of directors of Senti Biosciences, Inc. and was previously a member of the board of Senti s predecessor, Dynamics Special Purpose Corp. since March 2021. From March 2017 to February 2023, he served as a director at Evelo Biosciences, Inc., including as the Chair of its board of directors from September 2019 to June 2022. From 2017 until October 2022, Mr. Epstein was a consultant and executive partner at Flagship Pioneering. From May 2019 to October 2022, Mr. Epstein served on the board of directors and as Chairman of Axcella Health Inc. (formerly Axcella Therapeutics) and, from January 2017 to October 2022, Mr. Epstein served on the board of directors of Rubius Therapeutics, Inc. From 2010 to mid-2016, he served as the Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, he started and led Novartis Oncology and Molecular Diagnostic units. Under his leadership, Novartis oncology business grew to the second largest in the world. Early in his career, he was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton. Mr. Epstein holds a B.S. in pharmacy from Rutgers University College of Pharmacy and an M.B.A. in finance and marketing from Columbia University Graduate School of Business. We believe that Mr. Epstein is qualified to serve on our board of directors because of his extensive experience serving in executive roles in the life sciences industry and leading the development and commercialization of numerous therapeutics.